article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

G protein-coupled receptors (GPCRs) are a highly validated drug target family – accounting for 30-35 percent of all approved drugs. Despite this, the therapeutic potential of targeting most GPCRs remains untapped, as only 10 percent of GPCRs have been drugged.

Disease 59
article thumbnail

Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention

The Pharma Data

Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. I have spent the better part of my career working to make drugs safer. corticosteroids, beta-blockers, antidepressants).

article thumbnail

Human neuronal cells: possibilities in drug safety testing

Drug Target Review

These cells demonstrate considerable promise for uncovering drug-induced perturbations to neuronal function such as seizure, and their use extends further to sedation, anti-epileptic drug discovery and modelling of neurological diseases.

Drugs 112
article thumbnail

How the AI revolution can accelerate early drug discovery

Drug Target Review

“AI will not replace drug discovery scientists, but drug discovery scientists who use AI will replace those who don’t” – comment during EFMC meeting 2018 Progressing a drug molecule from concept to commercialisation typically takes 10-15 years and has high associated costs of up to $2 billion per launched drug, if all failures are factored in.

Drugs 105
article thumbnail

Therapeutic peptide developed for triple-negative breast cancer

Drug Target Review

The peptide in development is based on a 2018 Cleveland Clinic discovery and serves as a proof-of-concept for this type of drug for triple-negative breast cancer. 2 The cells of this cancer lack certain receptors so drugs designed to treat other subtypes of breast cancer will not work. 2008 December [2024 January 18]; 44(18):2799-2805.

Treatment 106
article thumbnail

Number of People in Portugal Criminally Sanctioned for Drugs Increasing

Common Sense for Drug Policy Blog

Number of People in Portugal Criminally Sanctioned for Drugs Increasing "The Supreme Court of Justice, considering that it was not intended to legalize drug use , but only to decriminalize less severe consumption , reestablishes the crime of drug use (article 40°, Decree-Law n. After 2008 (Fig. After 2008 (Fig.

Drugs 40